Compile Data Set for Download or QSAR
Report error Found 2909 Enz. Inhib. hit(s) with Target = 'Ubiquitin carboxyl-terminal hydrolase 30'
TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513559((R)-3-(5-(4-methyl-3-oxo-3,4-dihydro-2H-benzo[b][1...)
Affinity DataIC50: 0.100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513561((R)-3-(5-(4-methyl-3-oxo-3,4-dihydro-2H-benzo[b][1...)
Affinity DataIC50: 0.100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513562((R)-3-(1,1-dioxido-5-(3-oxo-3,4-dihydro-2H-benzo[b...)
Affinity DataIC50: 0.100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513564(3-(5-(4-methyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]o...)
Affinity DataIC50: 0.100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513567((R)-3-(5-(2′-methoxy-[1,1′-biphenyl]-3...)
Affinity DataIC50: 0.100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513568((R)-3-(5-([1,1'-biphenyl]-4-yl)-1,1- dioxido-1,2,5...)
Affinity DataIC50: 0.100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513570((R)-3-(5-([1,1'-biphenyl]-3-yl)-1,1- dioxido-1,2,5...)
Affinity DataIC50: 0.100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513572((R)-3-(5-(4-methoxy-[1,1'- biphenyl]-3-yl)-1,1-dio...)
Affinity DataIC50: 0.100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513574((R)-3-(5-(3'-methoxy-[1,1'- biphenyl]-3-yl)-1,1-di...)
Affinity DataIC50: 0.100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513575((R)-3-(5-(2'-methoxy-[1,1'- biphenyl]-4-yl)-1,1-di...)
Affinity DataIC50: 0.100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513576((R)-3-(1,1-dioxido-5-(4-(pyridin-4- yl)phenyl)-1,2...)
Affinity DataIC50: 0.100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513577((R)-3-(1,1-dioxido-5-(3-(pyridin-4- yl)phenyl)-1,2...)
Affinity DataIC50: 0.100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513578((R)-3-(5-(3-(1-methyl-1H-pyrazol- 4-yl)phenyl)-1,1...)
Affinity DataIC50: 0.100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513581((R)-3-(5-(3-chloro-4- morpholinophenyl)-1,1-dioxid...)
Affinity DataIC50: 0.100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513582((R)-3-(5-(3-morpholinophenyl)- 1,1-dioxido-1,2,5-t...)
Affinity DataIC50: 0.100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513584((R)-3-(1,1-dioxido-5-(3- phenylisoxazol-5-yl)-1,2,...)
Affinity DataIC50: 0.100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513586((R)-3-(1,1-dioxido-5-(3-phenyl- 1H-pyrazol-5-yl)-1...)
Affinity DataIC50: 0.100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513590((S)-3-(1,1-dioxido-5- (4-(pyridin-4- yl)phenyl)-1,...)
Affinity DataIC50: 0.100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513591((S)-3-(1,1-dioxido-5- (3-(pyridin-4- yl)phenyl)-1,...)
Affinity DataIC50: 0.100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513592((S)-3-(5-([1,1'- biphenyl-4-yl)-1,1- dioxido-1,2,5...)
Affinity DataIC50: 0.100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513593((S)-3-(5-([1,1'- biphenyl]-3-yl)-l,1- dioxido-1,2,...)
Affinity DataIC50: 0.100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513594((S)-3-(1,1-dioxido-5- (6-phenylpyridin-2-yl)- 1,2,...)
Affinity DataIC50: 0.100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513597((3R,4S)-3-(5-([1,1′-biphenyl]-4-yl)-1,1-diox...)
Affinity DataIC50: 0.100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513600((R)-3-(5-(6-methoxy-[1,1′-biphenyl]-3-yl)-1,...)
Affinity DataIC50: 0.100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513601((R)-3-(5-(2-methoxy-[1,1′-biphenyl]-4-yl)-1,...)
Affinity DataIC50: 0.100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513607((R)-3-(5-(9-methyl-9H-carbazol-3-yl)-1,1-dioxido-1...)
Affinity DataIC50: 0.100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513608((R)-3-(5-(2-morpholinopyridin-4-yl)-1,1-dioxido-1,...)
Affinity DataIC50: 0.100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513625((R)-3-(3-benzyl-2,2-dioxidobenzo[c][1,2,5]thiadiaz...)
Affinity DataIC50: 0.550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513627((R)-3-(1-benzyl-2,2-dioxido-1,4-dihydro-3H-benzo[c...)
Affinity DataIC50: 0.550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513630((R)-3-(7-(1-methyl-1H-pyrazol-4-yl)-2,2-dioxido-1,...)
Affinity DataIC50: 0.550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513631((R)-3-(2,2-dioxido-7-phenyl-1,4-dihydro-3H-benzo[c...)
Affinity DataIC50: 0.550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513632((R)-3-(1-methyl-2,2-dioxido-7-phenyl-1,4-dihydro-3...)
Affinity DataIC50: 0.550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513633((R)-3-(1-methyl-2,2-dioxido-6-phenyl-1,4-dihydro-3...)
Affinity DataIC50: 0.550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513518(US11091488, Example 1)
Affinity DataIC50: 0.550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513560((R)-3-(1,1-dioxido-5-(3-oxo-3,4-dihydro-2H-benzo[b...)
Affinity DataIC50: 0.550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513563((R)-3-(5-(4-(2-hydroxyethyl)-3-oxo-3,4-dihydro-2H-...)
Affinity DataIC50: 0.550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513565((R)-3-(5-(4-methoxy-3-morpholinophenyl)-1,1-dioxid...)
Affinity DataIC50: 0.550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513566((3R)-3-(1,1-dioxido-5-(1-(pyridin-2-yl)pyrrolidin-...)
Affinity DataIC50: 0.550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513569((R)-3-(6-([1,1'-biphenyl]-4-yl)-1,1- dioxido-1,2,6...)
Affinity DataIC50: 0.550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513571((R)-3-(6-([1,1'-biphenyl]-3-yl)-1,1- dioxido-1,2,6...)
Affinity DataIC50: 0.550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513579((R)-3-(6-(3-(1-methyl-1H-pyrazol- 4-yl)phenyl)-1,1...)
Affinity DataIC50: 0.550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513580((R)-3-(5-(4-morpholinophenyl)- 1,1-dioxido-1,2,5-t...)
Affinity DataIC50: 0.550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513585((R)-3-(1,1-dioxido-6-(3- phenylisoxazol-5-yl)-1,2,...)
Affinity DataIC50: 0.550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513587((R)-3-(1,1-dioxido-6-(3-phenyl- 1H-pyrazol-5-yl)-l...)
Affinity DataIC50: 0.550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513588((R) N-(1-cyanopyrrolidin-3-yl)-2-phenyl-6,7-dihydr...)
Affinity DataIC50: 0.550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513595(3-(1,1-dioxido-5-phenyl-1,2,5-thiadiazolidin-2-yl)...)
Affinity DataIC50: 0.550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513596(3-(1,1-dioxido-6-phenyl-1,2,6-thiadiazinan-2-yl)py...)
Affinity DataIC50: 0.550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513598((3S,4R)-3-methyl-4-(5-(3-(4-methylpiperazin-1-yl)p...)
Affinity DataIC50: 0.550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513599((3S,4R)-3-methyl-4-(5-(3-morpholinophenyl)-1,1-dio...)
Affinity DataIC50: 0.550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM513602((R)-3-(1,1-dioxido-5-(2-(trifluoromethyl)-1H-benzo...)
Affinity DataIC50: 0.550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

Displayed 1 to 50 (of 2909 total ) | Next | Last >>
Jump to: